Maze Therapeutics (MAZE) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.79

Estimate

-$0.75

Surprise

-5.1%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Maze Therapeutics (MAZE) reported a wider loss than forecast — adjusted EPS of -$0.79 against the -$0.75 estimate (a 5.1% shortfall).

• Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $49 — benzinga, 2026-11-10
• Maze Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-10
• Maze Therapeutics Q3 EPS $(0.79) Misses $(0.77) Estimate — benzinga, 2026-11-09

TrendMatrix currently rates MAZE Sell at 5.4/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -5.1% surprise compares with a -2.8% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$34.89

Price target

$54.41

Stop

$32.45

Upside to target

+55.9%

Reward-to-risk

3.7:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.94B

P/E (fwd)

-11.0

52-week range

$21.95–$53.65

Off 52-week high

35.0%

RSI (14)

61

Volume vs avg

0.13×

Score today

5.4/10